276 related articles for article (PubMed ID: 15099937)
1. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
6. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
[TBL] [Abstract][Full Text] [Related]
7. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
11. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks JR; Davidoff AM; Kerns BJ; Humphrey PA; Pence JC; Dodge RK; Clarke-Pearson DL; Iglehart JD; Bast RC; Berchuck A
Cancer Res; 1991 Jun; 51(11):2979-84. PubMed ID: 2032235
[TBL] [Abstract][Full Text] [Related]
13. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
[TBL] [Abstract][Full Text] [Related]
14. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
15. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
17. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
18. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
19. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
20. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
Guan X; Lang J; Bian M
Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
